Talk to an Scientist
Talk to an Scientist

Product

GOLDILOCKS™
biosimilars

100+ biosimilars in development. Pick yours

  • Bundled low cost media & feeds
  • 100+ pool-stage biosimilars
  • Royalty-free licensing
  • Skip 4 months
    of CLD

Program delays

Why biosimilar programs lose momentum — and how pre-developed cell lines help recover critical months

Biosimilar timelines are shaped by speed, cost, and first-mover advantage. Programs often lose time during cell line development, scale-up, and comparability work — where pre-developed cell lines can shorten the path and reduce execution risk.

  1. CLD Eats the Critical Path

    The 4-month problem

    • Stable CLD takes 3-4 months even on best platforms
    • Critical path delay = direct market lost

  2. Patent Cliffs Are Unforgiving

    The first-mover problem

    • Originator patents expire on fixed calendars
    • Late launches lose tier-1 payer formularies
    • Months lost = significant lifetime revenue lost

  3. Duplicate Industry Work

    The redundant-effort problem

    • Each sponsor re-develops the same cell lines
    • Wasted industry effort across overlapping programs

What’s In Inventory

The GOLDILOCKS™ biosimilars library

Pre-developed GOLDILOCKS-grade cell lines against leading reference biologics – available at two stages of development. License what you need; skip the work we’ve already done.

Pool-Stage Biosimilars

100+

stable pools, subcloning available

  • GOLDILOCKS transposase-derived stable pools
  • Initial pool CQA fingerprint collected
  • Subcloning + RCB pre-scoped per program
  • Broader library – pick your target reference

Clone-Stage Biosimilars

10

RCB-ready or near-RCB cell lines

  • Subcloned from GOLDILOCKS stable pools
  • Top-clones characterized and banked
  • Ready to advance to scale-up and tox
  • Most advanced – fastest path to IND

Licensing workflow

Standard licensing engagement runs in 4 steps. Material can ship to your CDMO within weeks of contract signature.

  1. WEEK 1

    SELECT TARGET

    • Identify your reference biologic
    • Check library availability + stage
    • Confirm fit-to-program timeline
  2. WEEK 2-3

    LICENSING

    • License terms (royalty-free)
    • Define scope: clone vs PD stage
    • Sponsor-specific scope locked
  3. WEEK 3-11

    ADVANCEMENT

    • Subclone from pool to clone
    • Optional: innovator comparability
    • Optional: 3L or 50L PD on the licensed line
  4. WEEK 11+

    TECH TRANSFER

    • RCB transferred to your CDMO
    • Locked process docs + analytical SOPs
    • Tech transfer support included
  5. OUTPUT

    LICENSED CELL LINE + SUPPORTING DOCS. AT YOUR SCALE-UP SITE

    • GOLDILOCKS-grade material continuity
    • Skip ~4 months of CLD
    • Continued purchase of Celltheon’s low COGs media option

Key advantages

TRIDENT is the first site-specific conjugation platform to combine native
Fc preservation, zero antibody engineering, and flexible DAR in a single off-the-shelf kit format.

  • Skip 4+ months of CLD

    Pool development, subcloning, top-clone selection, stability – already done. Pick up the cell line and advance directly toward scale-up.

  • GOLDILOCKS-grade titers

    Built on the same platform as custom Celltheon CLD – 7-14g/L pool titers, 10-20g/L clone titers.

  • Royalty-free licensing

    Commercial-friendly terms. No royalty burden on your therapeutic.

  • SUPERCELL™ host

    Same CHO-K1 host used for all biosimilars available -> platform with downstream Celltheon services (analytics, PD, 50L).

  • Optional innovator matching

    Add innovator procurement and comparability characterization

  • Tech transfer ready

    RCB + process documentation + analytical SOPs ready for direct handoff to your CDMO. Tech transfer support included.

Engagement options

Three ways to access GOLDILOCKS — check the library, license existing material, or co-develop a new program

Start with the full panel as the primary screening offer, then adjust scope with à la carte or bundled configurations. Volume-based pricing supports larger candidate sets by lowering the per-sample rate.

  • Most advanced
    License a preexisting clone

    Clone-stage biosimilar – most advanced

    RCB-ready or near-RCB cell line

    • 10 clone-stage biosimilars available
    • Fastest path – skip pool + subcloning
    • Titer + stability locked at clone
    • Direct path to your scale-up partner

    Ideal for: speed-critical programs vs major originators

    Talk to a Scientist
  • License a clone

    Rapid Pool-to-Clone stage biosimilar (broader options)

    Stable pool → subcloning, PD available as add-on

    • 100+ pool-stage biosimilars
    • Broader library breadth
    • Subclone + RCB
    • Lower entry point than clone licensing

    Ideal for: programs targeting newer or less-blockbuster originators

    Talk to a Scientist
  • Co-develop

    Custom biosimilar on GOLDILOCKS

    We build your reference if not in the library

    • Full GOLDILOCKS CLD program
    • Custom QA matching to innovator
    • Tech transfer at end of program
    • See Biosimilar Dev Services

    Ideal for: programs targeting references not yet in the library

    Talk to a Scientist
Frequently asked questions

Quick answers
to common questions

Quick answers about SUPERCELL™.

View more answers

SUPERCELL™ is a next-generation CHO-K1 host cell line purpose-built for difficult-to-express proteins. Derived from the original Puck laboratory CHO-K1 lineage, SUPERCELL™ delivers superior expression of challenging molecule formats—including scFvs, bispecifics, and non-mAb therapeutics—with higher yields and improved product quality compared to standard CHO-K1 platforms.

Discuss your molecule with our scientists

We don’t workaround — we innovate
and deliver

Explore whether OmniCHO™ is the right expression platform for your specific protein format.

Talk to a Scientist